{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:39:13Z","timestamp":1781685553113,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,19]]},"DOI":"10.7759\/cureus.99651","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T21:35:18Z","timestamp":1766180118000},"source":"Crossref","is-referenced-by-count":3,"title":["New-Onset Atrial Fibrillation Potentially Associated With Tirzepatide: A Case Report"],"prefix":"10.7759","author":[{"given":"Akhtar","family":"Purvez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mudhasir","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas JP","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021, 385:503-15. 10.1056\/NEJMoa2107519","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of tirzepatide in SURPASS-1, a randomized, double-blind trial","volume":"398","author":"Rosenstock J","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP, et al.. Efficacy and safety of tirzepatide in SURPASS-1, a randomized, double-blind trial. Lancet. 2021, 398:143-55. 10.1016\/S0140-6736(21)01324-6","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes (SURPASS-4)","volume":"398","author":"Del Prato S","year":"2021","unstructured":"Del Prato S, Kahn SE, Pavo I, et al.. Tirzepatide versus insulin glargine in type 2 diabetes (SURPASS-4). Lancet. 2021, 398:1811-24. 10.1016\/S0140-6736(21)02188-7","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the surpass-5 randomized clinical trial","volume":"327","author":"Dahl D","year":"2022","unstructured":"Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodr\u00edguez \u00c1. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the surpass-5 randomized clinical trial. J Am Med Assoc. 2022, 327:534-45. 10.1001\/jama.2022.0078","journal-title":"J Am Med Assoc"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck MA","year":"2022","unstructured":"Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022, 21:169. 10.1186\/s12933-022-01604-7","journal-title":"Cardiovasc Diabetol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1121387","article-title":"A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?","volume":"14","author":"Meng Z","year":"2023","unstructured":"Meng Z, Yang M, Wen H, Zhou S, Xiong C, Wang Y. A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?. Front Endocrinol (Lausanne). 2023, 14:1121387. 10.3389\/fendo.2023.1121387","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-023-01198-4","article-title":"Efficacy and safety of tirzepatide, dual GLP-1\/GIP\u00a0receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Zhou Q","year":"2023","unstructured":"Zhou Q, Lei X, Fu S, et al.. Efficacy and safety of tirzepatide, dual GLP-1\/GIP\u00a0receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2023, 15:222. 10.1186\/s13098-023-01198-4","journal-title":"Diabetol Metab Syndr"},{"key":"ref9","doi-asserted-by":"crossref","DOI":"10.1038\/s41366-023-01337-x","article-title":"Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials","volume":"47","author":"de Mesquita YL","year":"2023","unstructured":"de Mesquita YL, Pera Calvi I, Reis Marques I, et al.. Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials. Int J Obes. 2023, 47:883-92.","journal-title":"Int J Obes"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.03062","article-title":"Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus","volume":"64","author":"Ferdinand KC","year":"2014","unstructured":"Ferdinand KC, White WB, Calhoun DA, et al.. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014, 64:731-7. 10.1161\/HYPERTENSIONAHA.114.03062","journal-title":"Hypertension"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2022.101405","article-title":"Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: a comprehensive review ranging from sulphonylureas to SGLT2 inhibitors","volume":"48","author":"Scheen AJ","year":"2022","unstructured":"Scheen AJ. Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: a comprehensive review ranging from sulphonylureas to SGLT2 inhibitors. Diabetes Metab. 2022, 48:101405. 10.1016\/j.diabet.2022.101405","journal-title":"Diabetes Metab"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59101760","article-title":"Associations between oral glucose-lowering agents and increased risk for life-threatening arrhythmias in patients with type 2 diabetes mellitus-a literature review","volume":"59","author":"Tudoran C","year":"2023","unstructured":"Tudoran C, Tudoran M, Giurgi-Oncu C, Abu-Awwad A, Abu-Awwad SA, Voi\u0163\u0103-Mekere\u015f F. Associations between oral glucose-lowering agents and increased risk for life-threatening arrhythmias in patients with type 2 diabetes mellitus-a literature review. Medicina (Kaunas). 2023, 59:1760. 10.3390\/medicina59101760","journal-title":"Medicina (Kaunas)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2223-3652.2015.06.03","article-title":"Atrial fibrillation in patients with diabetes: molecular mechanisms and therapeutic perspectives","volume":"5","author":"De Sensi F","year":"2015","unstructured":"De Sensi F, De Potter T, Cresti A, Severi S, Breithardt G. Atrial fibrillation in patients with diabetes: molecular mechanisms and therapeutic perspectives. Cardiovasc Diagn Ther. 2015, 5:364-73. 10.3978\/j.issn.2223-3652.2015.06.03","journal-title":"Cardiovasc Diagn Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2024.03.031","article-title":"Effects of glucagon-like peptide-1 receptor agonists on atrial fibrillation recurrence after catheter ablation","volume":"10","author":"Satti DI","year":"2024","unstructured":"Satti DI, Karius A, Chan JS, et al.. Effects of glucagon-like peptide-1 receptor agonists on atrial fibrillation recurrence after catheter ablation. JACC Clin Electrophysiol. 2024, 10:1848-55. 10.1016\/j.jacep.2024.03.031","journal-title":"JACC Clin Electrophysiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker DJ","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018, 27:740-56. 10.1016\/j.cmet.2018.03.001","journal-title":"Cell Metab"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/hrs guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"149","author":"Joglar JA","year":"2024","unstructured":"Joglar JA, Chung MK, Armbruster AL, et al.. 2023 ACC\/AHA\/ACCP\/hrs guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2024, 149:e1-e156. 10.1161\/CIR.0000000000001193","journal-title":"Circulation"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.85366","article-title":"Life-threatening ventricular fibrillation linked to high-dose tirzepatide-induced gastrointestinal side effects","volume":"17","author":"Kammaripalle TK","year":"2025","unstructured":"Kammaripalle TK, Giordano JR, Rana H, Gade A, Reddy S. Life-threatening ventricular fibrillation linked to high-dose tirzepatide-induced gastrointestinal side effects. Cureus. 2025, 17:e85366. 10.7759\/cureus.85366","journal-title":"Cureus"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.46373","article-title":"Beyond blood sugar: investigating the cardiovascular effects of antidiabetic drugs","volume":"15","author":"Ahmad BA","year":"2023","unstructured":"Ahmad BA, Sanghani IM, Sayabugari R, et al.. Beyond blood sugar: investigating the cardiovascular effects of antidiabetic drugs. Cureus. 2023, 15:e46373. 10.7759\/cureus.46373","journal-title":"Cureus"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.80164","article-title":"Exploring the effects of tirzepatide on obstructive sleep apnea: a literature review","volume":"17","author":"Wen J","year":"2025","unstructured":"Wen J, Nadora D, Truong A, et al.. Exploring the effects of tirzepatide on obstructive sleep apnea: a literature review. Cureus. 2025, 17:e80164. 10.7759\/cureus.80164","journal-title":"Cureus"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.38379","article-title":"Tirzepatide: a promising drug for type 2 diabetes and beyond","volume":"15","author":"Dutta P","year":"2023","unstructured":"Dutta P, Kumar Y, Babu AT, et al.. Tirzepatide: a promising drug for type 2 diabetes and beyond. Cureus. 2023, 15:e38379. 10.7759\/cureus.38379","journal-title":"Cureus"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2165\/11633140-000000000-00000","article-title":"Drug-induced atrial fibrillation","volume":"72","author":"Kaakeh Y","year":"2012","unstructured":"Kaakeh Y, Overholser BR, Lopshire JC, Tisdale JE. Drug-induced atrial fibrillation. Drugs. 2012, 72:1617-30. 10.2165\/11633140-000000000-00000","journal-title":"Drugs"},{"key":"ref22","article-title":"Recurrent atrial fibrillation episodes related to monosodium glutamate: a case report","volume":"27","author":"Purvez A","year":"2023","unstructured":"Purvez A, Valentine CM, Monfredi OJ, et al.. Recurrent atrial fibrillation episodes related to monosodium glutamate: a case report. Anesth Pain Intensive Care. 2023, 27:613-15.","journal-title":"Anesth Pain Intensive Care"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.90811","article-title":"The need for uniform labeling regulations for monosodium glutamate to address health risks and consumer protection","volume":"17","author":"Purvez A","year":"2025","unstructured":"Purvez A, Valentine MC. The need for uniform labeling regulations for monosodium glutamate to address health risks and consumer protection. Cureus. 2025, 17:e90811. 10.7759\/cureus.90811","journal-title":"Cureus"},{"key":"ref24","doi-asserted-by":"crossref","DOI":"10.7326\/aimcc.2025.0351","article-title":"Monosodium glutamate and atrial fibrillation in a 78-year-old woman: a case report","volume":"4","author":"Purvez A","year":"2025","unstructured":"Purvez A, Valentine CM, Bashir M. Monosodium glutamate and atrial fibrillation in a 78-year-old woman: a case report. AIM Clinical Cases. 2025, 4:","journal-title":"AIM Clinical Cases"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/443216-new-onset-atrial-fibrillation-potentially-associated-with-tirzepatide-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T21:35:20Z","timestamp":1766180120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/443216-new-onset-atrial-fibrillation-potentially-associated-with-tirzepatide-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.99651","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,19]]}}}